• In March 2026, PROCEPT BioRobotics announced that the European Association of Urology updated its guidelines to give Aquablation therapy a strong recommendation as a surgical option for men with benign prostatic hyperplasia, particularly those seeking to preserve ejaculatory function.
• This upgrade, grounded in a large body of randomized and long-term clinical evidence and aligned with support from bodies such as NICE in the UK, further embeds Aquablation within mainstream urologic practice and may influence hospital adoption decisions.
• We will now examine how Aquablation’s new strong recommendation in European guidelines could reshape PROCEPT BioRobotics’ longer-term investment narrative.

Find 62 companies with promising cash flow potential yet trading below their fair value.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can become a core surgical option in BPH and support a growing base of recurring procedures, even as the company remains unprofitable and dependent on one primary platform. The EAU’s strong recommendation strengthens the near term adoption catalyst around HYDROS placements and procedure growth, but it does not remove key risks around reimbursement pressure, operating losses and the challenge of converting early hospital accounts into consistent, high volume users.

Among recent announcements, the March 12, 2026 update on HYDROS’s international expansion feels most connected to the new EAU guidance. Together, HYDROS’s AI enabled platform and a strong European guideline endorsement could matter for hospital purchasing decisions, particularly in countries where NICE and now the EAU provide converging clinical validation. For investors, that pairing sits at the heart of the upside case that broader system placements and higher utilization could eventually improve margins and scale the installed base.

Yet alongside this stronger clinical validation, investors should still weigh the risk that ongoing reimbursement pressure on urology procedures could limit how far and how fast adoption can realistically go...

PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028.

Uncover how PROCEPT BioRobotics' forecasts yield a $32.50 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming roughly 26 percent annual revenue growth to about US$624.2 million by 2029 and a swing to US$43.1 million in earnings, so this kind of EAU endorsement could either reinforce that bullish view on faster adoption or prompt a rethink if reimbursement or hospital capital constraints prove more restrictive than those forecasts allow.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

No Opportunity In PROCEPT BioRobotics?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.